With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk shares rose Monday as the company said it would present new data on the ability of semaglutide, the active ...

By Alberto Alerigi SAO PAULO (Reuters) -Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide ...

While the number of prescription fills for GLP-1 receptor agonists has continued to increase, health Insurance coverage for ...

The War and Treaty singer Michael Trotter Jr. tells PEOPLE ahead of the 'Opry 100: A Live Celebration' in Nashville on March ...

Drug compounders are moving to block the FDA’s decision that Novo Nordisk A/S’s weight loss drug is no longer in shortage, ...

The FDA ordered compounding pharmacies to stop making copycat versions of weight loss drugs like Ozempic and Zepbound now ...

In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

The FDA wants bulk production of copycat versions of popular weight-loss drugs to stop, but telehealth companies and compounding pharmacies ...